02:47:53 EDT Sun 17 Oct 2021
Enter Symbol
or Name

Login ID:
Juva Life Inc
Symbol JUVA
Shares Issued 126,086,161
Close 2021-10-13 C$ 0.255
Recent Sedar Documents

Juva files U.S. patent for non-cannabinoid molecules

2021-10-14 00:54 ET - News Release

Mr. Doug Chloupek reports


Juva Life Inc. has advanced the JUVA-19 class of compounds into formal development.

JUVA-19 is a non-cannabinoid small molecule isolated from cannabis with previous unappreciated broad spectrum anti-inflammatory properties. Preclinical results demonstrate that JUVA-19 inhibits IL1-beta and TNF-alpha in a dose-dependent manner. Additionally, the company has identified candidate targets consistent with the regulation of oxidative stress and inflammation.

Juva Life is availing itself of the significant body of literature suggestive of therapeutic benefits of cannabis coupled to modern drug discovery and deep learning tools. The company's strategy is to develop natural and semi-synthetic compositions alone and in combination for the consumer anti-inflammatory marketplace and, in parallel, chemically optimize compositions for select pharmaceutical indications.

The company's business strategy is to leverage its unique knowledge of the chemistry and anti-inflammatory mode of action of non-cannabinoid compositions contained within cannabis to develop safe and effective therapeutics. The company intends to develop products through preclinical in vivo validation studies and partner with leading pharma and consumer companies seeking anti-inflammatory bioactives for their product pipelines. On Oct. 6, 2021, the company filed a provisional patent with the U.S. Patent and Trademark Office (USPTO) on the method of use of the natural compositions and composition of matter claims on non-naturally occurring semi-synthetic and synthetic analogues.

Company chief executive officer Doug Chloupek stated, "We are pleased of the progress of our internal research and development activities."

Mr. Chloupek continued, "Our next steps are to build upon our initial findings by profiling the Juva-019 class of compounds in gold standard in vivo models of inflammation, paving the way for evidenced-based product development."

In separate news, the company is pleased to announce the appointment of Dr. Peter Beitsch to its board of directors, effective immediately.

Dr. Beitsch has held numerous positions in national surgical societies, including the American Society of Breast Surgeons, where he served as president of the society in 2013 and 2014, first chairman of the membership committee from 2001 to 2014, program director for the 2005 annual meeting in Los Angeles, and board of directors member from 2006 to 2009 and from 2012 to 2015. He has served on the executive committee of the Society of Surgical Oncology from 2008 to 2010, the general surgical oncology committee of the American Board of Surgery and was a national ultrasound faculty for the American College of Surgeons.

Dr. Beitsch has presented internationally, and is actively involved in breast cancer and melanoma research. He has written major articles in peer-reviewed medical journals, including the New England Journal of Medicine, the Journal of the American Medical Association, the Proceedings of the National Academy of Science, Journal of Clinical Oncology and the Annals of Surgical Oncology.

Mr. Chloupek stated: "I am very pleased to welcome Dr. Beitsch to our board today. The timing is excellent as we ramp our investigative endeavours into new and exciting compounds. Dr. Beitsch has provided excellent advice and insights through his previous role as an adviser to the company, and we are looking forward to his expanded role."

About Juva Life Inc.

Juva Life is employing state-of-the-art science to discover, develop and commercialize safe and effective cannabis products. The company is executing against its 2018 road map, initially starting with standardization of cultivation, extraction and formulation to offer consumers reproducible benefits. Juva is building upon these natural product process chemistry skills to now include discovery pharmacology. The company will leverage revenue derived from its retail operations to advance Juva-019 and other potentially valuable non-cannabinoid bioactives for consumer and pharma products applications. Juva is working to bring the cannabis market face to face with the sector's next-generation investment-grade business model.

We seek Safe Harbor.

© 2021 Canjex Publishing Ltd. All rights reserved.